Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rallybio (RLYB) EBIT (2023 - 2025)

Historic EBIT for Rallybio (RLYB) over the last 3 years, with Q3 2025 value amounting to -$6.9 million.

  • Rallybio's EBIT rose 4260.73% to -$6.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$38.3 million, marking a year-over-year increase of 4534.29%. This contributed to the annual value of -$60.5 million for FY2024, which is 2335.68% up from last year.
  • Rallybio's EBIT amounted to -$6.9 million in Q3 2025, which was up 4260.73% from -$10.1 million recorded in Q2 2025.
  • Rallybio's 5-year EBIT high stood at -$6.9 million for Q3 2025, and its period low was -$21.1 million during Q4 2023.
  • Its 3-year average for EBIT is -$15.1 million, with a median of -$17.0 million in 2024.
  • Its EBIT has fluctuated over the past 5 years, first crashed by 769.02% in 2024, then skyrocketed by 5112.95% in 2025.
  • Quarter analysis of 3 years shows Rallybio's EBIT stood at -$21.1 million in 2023, then soared by 45.02% to -$11.6 million in 2024, then skyrocketed by 40.34% to -$6.9 million in 2025.
  • Its EBIT stands at -$6.9 million for Q3 2025, versus -$10.1 million for Q2 2025 and -$9.7 million for Q1 2025.